Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.